RegeneRx President and CEO to Speak at 7th Annual BIO Investor Forum
REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) announced today that J.J. Finkelstein, RegeneRx’s president and chief executive officer, will present a company update at the 7th Annual BIO Investor Forum in San Francisco, CA, on Thursday, October 30, 2008 at 2:00 p.m. ET. To listen and view the presentation investors may either visit RegeneRx’s homepage at www.regenerx.com or click on the following link: http://phx.corporate-ir.net/phoenix.zhtml?c=144396&p=IROL- EventDetails&EventID=2004078 (Due to its length, this URL may need to be copied/pasted into your Internet browser’s address field. Remove the extra space if one exists.) An archived copy of the presentation will be available on RegeneRx’s website.
About RegeneRx Biopharmaceuticals, Inc.
RegeneRx is focused on the discovery and development of novel peptides to accelerate tissue and organ repair. Currently, RegeneRx is developing three product candidates, RGN-137, RGN-259 and RGN-352 for dermal, ophthalmic, and cardiovascular tissue repair, respectively. The Company is also developing RGN-457 for use in pulmonary indications such as cystic fibrosis. These product candidates are based on TB4, a 43-amino acid, naturally occurring peptide, in part, under an exclusive world-wide license from the National Institutes of Health. RegeneRx holds over 60 world-wide patents and patent applications related to novel peptides and is currently sponsoring three Phase II chronic dermal wound healing clinical trials, a Phase II ophthalmic wound healing clinical trial, and a Phase I parenteral (injectable) clinical trial supporting systemic delivery of RGN-352 for acute cardiovascular indications.
About Thymosin beta 4 (TB4)
TB4 is a synthetic version of a naturally occurring peptide present in virtually all human cells. It is a first-in-class multi-faceted molecule that promotes endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition, and down-regulates inflammation. RegeneRx has identified several molecular variations of TB4 that may affect the aging of skin, among other properties, and could be important candidates as active ingredients in pharmaceutical and consumer products. Researchers at the National Institutes of Health, and at other academic institutions throughout the U.S., have published numerous scientific articles indicating TB4′s in vitro and in vivo efficacy in accelerating wound healing and tissue protection under a variety of conditions. Key publications related to TB4′s cardio-protective effects have been published in Nature and Circulation. Abstracts of these and other scientific papers related to TB4′s mechanisms of action may be viewed at RegeneRx’s web page: www.regenerx.com.
Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of The Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the words “project,”"believe,”"anticipate,”"plan,”"expect,”"estimate,”"intend,”"should,”"would,”"could,”"will,”"may” or other similar expressions and include statements regarding the safety and efficacy of RGN-137, RGN-259, RGN-352, and RGN-457. Actual results may differ materially from those indicated or implied by such forward-looking statements because the Company’s product candidates may not demonstrate safety and/or efficacy in current or future clinical trials or as a result of various important factors described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” sections of the annual report on Form 10-K for the year ended December 31, 2007 filed with the SEC on March 28, 2008 and other periodic reports filed with the SEC. Any forward-looking statements in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company anticipates that subsequent events and developments may cause its views to change, and the Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.